Dual function miR-205 is positively associated with ER and negatively with five-year survival in breast cancer patients
Background - Precise molecular characterization of breast cancer, especially triple negative (TNBC) as the most lethal subtype, is needed to stratify patients for the individual treatment approach. MicroRNA-205 (miR-205) has tumor-suppressive and oncogenic functions across different cancers. Therefo...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
17 August 2022
|
| In: |
Pathology, research and practice
Year: 2022, Volume: 238, Pages: 1-8 |
| ISSN: | 1618-0631 |
| DOI: | 10.1016/j.prp.2022.154080 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.prp.2022.154080 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0344033822003247 
|
| Author Notes: | Nina Petrović, Lidija Todorović, Milica Nedeljković, Ana Božović, Zoran Bukumirić, Nasta Dedović Tanić, Snežana Jovanović-Ćupić, Ahmad Šami, Vesna Mandušić |
| Summary: | Background - Precise molecular characterization of breast cancer, especially triple negative (TNBC) as the most lethal subtype, is needed to stratify patients for the individual treatment approach. MicroRNA-205 (miR-205) has tumor-suppressive and oncogenic functions across different cancers. Therefore, miR-205 might have a different role in TNBC and estrogen receptor (ER) positive BC. Our aim was to investigate how miR-205 expression is associated with ER/progesteron receptor status, clinical parameters, pathohistological characteristics of BC, and survival of patients - Methods - We determined miR-205 relative expressions in 73 primary breast tumors (50 TNBC and 23 ER+) by quantitative Real-time polymerase chain reaction (qPCR) and compared it to clinicopathological characteristics and outcome. - Results - The highest levels of miR-205 were in the ER+ /PR+ group, and the lowest in the TNBC group (p = 0.009). Significantly higher levels of miR-205 were also observed in the ER+ compared with the ER-negative group, regardless of the PR status (p = 0.002). Low miR-205 expression level was associated with prognostic stage III in TNBC samples (p = 0.049). Patients who received adjuvant chemotherapy had significantly lower levels of miR-205 (p = 0.016). Patients who received hormone therapy had significantly higher levels of miR-205 (p = 0.007). The low-miR-205 patients had significantly higher 5-year survival rates (p = 0.041). - Conclusion - The expression of miR-205 in BC is subtype-specific and high expression is associated with the ER+ tumors. The miR-205 expression might be a useful marker of TNBC progression. High miR-205 expression had a detrimental effect on BC patient outcome. Our results indicate that miR-205 might be utilized in clinical practice as a biomarker and an adjunct parameter for the selection of the most effective therapeutic modality. |
|---|---|
| Item Description: | Online verfügbar: 17 August 2022, Artikelversion: 19 August 2022 Gesehen am 21.08.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1618-0631 |
| DOI: | 10.1016/j.prp.2022.154080 |